The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.

@article{Hantschel2007TheBT,
  title={The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.},
  author={Oliver Hantschel and Uwe Rix and Uwe Schmidt and Tilmann B{\"u}rckst{\"u}mmer and Michael Kneidinger and Gregor A. Sch{\"u}tze and Jacques Colinge and Keiryn L. Bennett and Wilfried Ellmeier and Peter Valent and Giulio Superti-Furga},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2007},
  volume={104 33},
  pages={13283-8}
}
Dasatinib is a small-molecule kinase inhibitor used for the treatment of imatinib-resistant chronic myelogenous leukemia (CML). We have analyzed the kinases targeted by dasatinib by using an unbiased chemical proteomics approach to detect binding proteins directly from lysates of CML cells. Besides Abl and Src kinases, we have identified the Tec kinases Btk and Tec, but not Itk, as major binders of dasatinib. The kinase activity of Btk and Tec, but not of Itk, was inhibited by nanomolar… CONTINUE READING